Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
about
Measurable residual disease testing in acute myeloid leukaemia.Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.Minimal Residual Disease Eradication in CML: Does It Really Matter?Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment.BCR-ABL1 tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia.Treatment-free remission in patients with chronic myeloid leukemia.Treatment-Free Remission: a New Therapeutic Goal in Chronic Myelogenous Leukemia.Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response.Deeper molecular response is a predictive factor for treatment-free remission after imatinib discontinuation in patients with chronic phase chronic myeloid leukemia: the JALSG-STIM213 study.First-line therapy for chronic phase CML: selecting the optimal BCR-ABL1-targeted TKI.Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation.Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia.Dasatinib cessation after deep molecular response exceeding 2 years and natural killer cell transition during dasatinib consolidation.How I manage relapse of chronic myeloid leukaemia after stopping tyrosine kinase inhibitor therapy.Dasatinib dose management for the treatment of chronic myeloid leukemia.Revisiting the need for bone marrow examination in chronic myeloid leukemia.Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study.Tyrosine Kinase Inhibitors in the Treatment of Chronic-Phase CML: Strategies for Frontline Decision-making.A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea.When to Stop Tyrosine Kinase Inhibitors for the Treatment of Chronic Myeloid Leukemia.Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission.Chronic myeloid leukemia patients and treatment-free remission attitudes: a multicenter survey.First-line treatment strategies for newly diagnosed chronic myeloid leukemia: a network meta-analysisAllosterische KinaseinhibitorenChronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal
P2860
Q30234914-595BC22F-F490-460C-9021-EAF97373E943Q33593877-FE66F034-CB49-49F9-A997-384841A38BFDQ38602633-340AC367-7176-4F50-9908-4AC3D4C3BF5EQ38681424-6A9B50EA-43F9-4C7C-8BAD-E9C85BD040F8Q39350678-B4F1A360-660B-4A20-93D1-A93F08B5D2D9Q39423384-CAD30BC1-0CD5-4754-ADDE-396919F1C763Q45304786-C88CB853-F733-4E8C-AB26-CD1E16223E09Q45348850-664DF958-E919-455E-A6A0-A6301C61C892Q47767989-4F848719-E84F-4089-9B1E-F0927AB429FEQ47917650-596775E1-4A40-4ACF-B69F-B8167D61BCB3Q47929120-06CD6EE9-594C-457E-AE00-FD5C6DF4B81CQ48029208-24FFC3D9-A570-45A1-A1EB-9B95712CDF10Q48146023-D383419E-B368-40E6-9377-D3ACA8AA6A00Q48162932-5E2FB670-7746-4789-B83B-92AE62C01291Q48165102-191B437E-144C-4E58-B1D5-6E08313E85DBQ48193546-32F3D2B6-B683-467D-B33A-99C52BC9A677Q50422379-D9C4D35B-E331-4DA2-8E24-63B47E62D30DQ52567954-8C6B2939-5758-4480-AE4F-A025CA700637Q53077187-58020867-A4DB-4F3E-BD6A-F8E36922EDC1Q53703550-AE5464C8-09B9-4CC6-BCF2-6E54FF87B09CQ55177555-FBF94BE4-CEEA-48B6-A8C2-BDC22A0FC376Q55345383-DE909190-8A19-4D43-8C2C-2E7C3D1F8C45Q57069646-557F6E35-C8E0-4AE1-A9DC-B6696D090C6CQ57902738-5BA3F0FC-7171-42BA-ABCA-4B23BC946430Q58751747-FF843EB7-5211-411C-9247-F49EB94C8EA7
P2860
Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Discontinuation of dasatinib o ...... ysis of the STOP 2G-TKI study.
@en
type
label
Discontinuation of dasatinib o ...... ysis of the STOP 2G-TKI study.
@en
prefLabel
Discontinuation of dasatinib o ...... ysis of the STOP 2G-TKI study.
@en
P2093
P50
P1433
P1476
Discontinuation of dasatinib o ...... ysis of the STOP 2G-TKI study.
@en
P2093
Agnès Guerci-Bresler
Aude Charbonnier
Bruno Villemagne
France Intergroupe des Leucémies Myéloïdes Chroniques
Franck E Nicolini
François-Xavier Mahon
Gabriel Etienne
Gaelle Guillerm
Hyacinthe Johnson-Ansah
Jean-Christophe Ianotto
P304
P356
10.1182/BLOOD-2016-09-742205
P407
P577
2016-12-08T00:00:00Z